Device for treating gait deficit caused by multiple sclerosis receives FDA marketing authorization
Helius Medical Technologies’ groundbreaking PoNS device for short-term treatment of gait deficit due to multiple sclerosis has received marketing authorization from the U.S. Food and Drug Administration (FDA).